WO1998008831A1 - Traitement preventif ou curatif de la maladie d'alzheimer - Google Patents
Traitement preventif ou curatif de la maladie d'alzheimer Download PDFInfo
- Publication number
- WO1998008831A1 WO1998008831A1 PCT/JP1997/002883 JP9702883W WO9808831A1 WO 1998008831 A1 WO1998008831 A1 WO 1998008831A1 JP 9702883 W JP9702883 W JP 9702883W WO 9808831 A1 WO9808831 A1 WO 9808831A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- disease
- salt
- alzheimer
- phenyl
- cells
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Definitions
- the present invention is based on the effect of using 2-phenyl-1,2-benzoy'noselenazole 3- (2H) -one or a salt thereof as an active ingredient and reducing the neurotoxicity induced by ⁇ -mamiloid protein. Prevention and treatment of Alzheimer's disease. Background art
- acetylcholinesterase inhibitors such as physostigmine or tetrahydridoaminoacridine ( ⁇ ) are used in some countries. Attempts have been made to develop nervous system drugs, but their effects have not been fully defined.
- pathological features of Alzheimer's disease include the accumulation of senile plaques and PHFs (paired helical filaments) in the brain.
- a / S The / 3 amyloid protein (A / S), which is the main component of the senile plaque, is an insoluble peptide consisting of about 40 amino acid residues, and AyS itself produces neurons? : It has been shown to be specifically impaired, in particular, caused by aggregated A / 5 rather than solubilized A.
- the present inventors have conducted intensive studies to find a low-molecular compound having a neurotoxicity-reducing effect of A and capable of passing through the cerebrovascular blood flow barrier (BBB). As a result, 2-phenyl-1,2-benzine was found.
- the inventors of the present invention have found out that bisoselenazo-l-3 (2H) -one has an excellent action, and have completed the present invention.
- the present invention provides a preventive / therapeutic agent for Alzheimer's disease, comprising 2-phenyl-1,2-benzoisoselenazo-3 (2H) -one or a salt thereof as an active ingredient.
- the present invention also provides an inhibitor of neuronal cell death caused by / S amiloid protein containing 2-phenyl-1,2-benzoisoselenabul-13 (2H) -one or a salt thereof as an active ingredient. Things.
- the present invention provides a prophylactic / therapeutic composition for Alzheimer's disease, comprising 2-phenyl-1,2-benzoisoselenabul-3 (2H) one or a salt thereof and a pharmaceutically acceptable carrier.
- a prophylactic / therapeutic composition for Alzheimer's disease comprising 2-phenyl-1,2-benzoisoselenabul-3 (2H) one or a salt thereof and a pharmaceutically acceptable carrier.
- the present invention relates to a nerve cell comprising a 9-amiloid protein containing 2-phenyl-1,2-benzoisoselenabul-3 (2H) -one or a salt thereof and a pharmaceutically acceptable carrier.
- the present invention provides a death inhibitor composition.
- the present invention provides the use of 2-phenyl-1,2-benzisoselenazolu-ru-3 (2H) -one or a salt thereof for producing a prophylactic / therapeutic agent for Alzheimer's disease.
- the present invention provides use of 2-phenyl-1,2-benzisoselenabu-lue 3 (2H) one or a salt thereof for the production of a nerve cell death inhibitor by / 8-amyloid protein. It is.
- the present invention relates to 2-phenyl-1,2-benzoisoselenabul-3 (2H)
- the present invention provides a method for treating Alzheimer's disease, which comprises administering an effective amount of -on or a salt thereof to a patient.
- the present invention is based on neuronal cell death caused by amyloid protein, which comprises administering to a patient an effective amount of 2-phenyl-1,2-benbuisoselenabul-3 (2H) one or a salt thereof.
- a method for treating a disease is provided.
- a / S is discovered as a major component of senile plaques, one of the pathological features of Alzheimer's disease, and consists of 39 to 43 amino acid residues. It is known to be toxic and induce cell death.
- PC 12 cells have the ability to induce cell death in the presence of A ⁇ , and the neurotoxicity of 1/3 is increased by the addition of 2-phenyl-1,2-benbuisoselenazol-3 (2 ⁇ ) one. It was found to suppress death.
- the 2-phenyl-2-benzoisoselenazolu-3 (2H) -one used in the present invention is a known compound, and has already been used as an anti-rheumatic agent (Japanese Patent Application Laid-Open No. 57-56427). ), Anti-inflammatory agent (Japanese Patent Application Laid-Open No. 57-67568), oxidative stress-based therapeutic agent for the disease (Japanese Patent Application Laid-Open No.
- liver disease Therapeutic agent JP-A-63-27431
- malignant tumor therapeutic agent JP-A-63-185358
- renal disease therapeutic agent JP-A-64) JP-A-5-56615
- a therapeutic agent for ischemic encephalopathy Japanese Patent Laid-Open No. 1-113113
- a therapeutic agent for heart disease Japanese Patent Laid-Open No. 1131114
- Gastrointestinal disease therapeutic agent Japanese Patent Application Laid-Open No. 1-132252
- radiation damage therapeutic agent Japanese Patent Application Laid-Open No. 11-357718
- infectious agent Japanese Patent Application Laid-Open No. Japanese Patent Application Laid-Open No. 08-25825
- an agent for inhibiting restenosis after percutaneous coronary angioplasty there is no known effect of preventing or treating Alzheimer's disease.
- Ebselen or a salt thereof strongly suppresses the toxic death of neurons induced by A / S as shown in the Examples below. It also strongly suppresses the production of hydrogen peroxide by NO derived from A / S. Therefore, ebselen or its salt is a predictor of Alzheimer's disease. It is considered to be effective as an anti-therapeutic agent. '
- the agent for preventing or treating Alzheimer's disease of the present invention may be prepared by adding Ebselen or a salt thereof to an excipient, a binder, a lubricant, a disintegrant, a coating agent, an emulsifier, a suspending agent, a solvent, and a stabilizer, if necessary.
- a pharmaceutically acceptable carrier such as an absorption aid, an ointment base or the like is added as appropriate, or ribosome formation is carried out, and the preparation is made into a dosage form for oral administration, injection, rectal administration, etc. according to a conventional method. It is obtained by converting
- Formulations for oral administration include granules, tablets, dragees, capsules, soft carbs, pills, solutions, emulsions, suspensions, etc.
- Formulations for injection administration include intravenous injection, muscle Suppositories, capsules, and the like are preferable as preparations for intrarectal administration, such as for intravenous injection, subcutaneous injection, and intravenous injection.
- the dose varies depending on the route of administration, the age of the patient, symptoms, etc., but in general, for oral administration per adult daily, 100 to 20,000 mg, especially 200 to 1,000 mg, of ebselen or its salt , 100 mg is preferable, and it is administered once or in several divided doses.
- Example 1 Inhibitory effect of ebselen on neuronal death in the presence of A8:
- PC12 cells in a 100 lysed dish manufactured by Corning
- polylysine manufactured by Sigma
- DMEM medium containing 100% FCS and 5% horse serum
- PC12 cells (lxl0, 6 dishes, 7 dishes) on a polylysine-coated 100 dish, and DMEM containing 5% FCS, 5 OngZ NGF and 1% horse serum to differentiate PC12 cells The cells were cultured in the medium for 7 days. After the thus prepared PC 1 2 cells were ⁇ by piperidines Tti ring, were prepared to the cell suspension, poly Rijinko one you encountered a 9 6 well di Mesh 1 X 1 0 4 of (pieces / well) cells was sown.
- a / S (manufactured by BACHEM FEINCHMIKALIEN AG) was added to a final concentration of 10 / ⁇ M and ebselen to a final concentration of 0.1, 1.0 and 2.5M, respectively.
- a sulfur-substituted form of ebselen which does not have glucan peroxidase-like activity, is 2-phenyl-1,2-benzothiabyl-3 (2H) -on ( (Obtained from Natsu Yuichi Man Co.) at the same concentration and in the same manner. Ebselen or 2-phenyl
- the cells were cultured 48 hours after the addition of 1,2-benzothiazol-3 (2H) -one.
- MTT reagent [3- (4,5-dimethylthiazole-2-yl-)-1,2,5-diphenyltetrazolium bromide) to the cultured cells treated as described above, and incubate for 4 hours. Destroyed. The following procedure was performed according to the so-called MTT method based on a colorimetric reaction based on the reduction reaction of the same reagent, and the viability of the cells in the suspension was determined (Behl, et al., Cell, 77: 817-827, 1994).
- the T test was performed on the A 10 M-added group.
- PC12 cells rat-derived, (Chromophilic cell tumor) was cultured and subcultured.
- SNAP was added to the PC12 cells in the adhered DMEM medium obtained above. 10 M and Ebselen 2.5 M were added, and 'SNAP 10 M alone was added to the control group, and each was incubated for 3 hours.
- DA Molecular Probes, Inc.
- the suspension was analyzed by FACS (Fluorescence-Activated Cell Sorting), and the amount of fluorescent substance 2 ', 7'-dichlorofluorescin (DCFH) oxidized by peroxide was measured. Does adding hydrogen produce hydrogen peroxide?
- the agent for preventing and treating Alzheimer's disease of the present invention suppresses nerve cell death in the presence of AS and is useful for preventing or treating Alzheimer's disease.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU38669/97A AU3866997A (en) | 1996-08-27 | 1997-08-20 | Preventive or remedy for alzheimer's disease |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP22551296 | 1996-08-27 | ||
JP8/225512 | 1996-08-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998008831A1 true WO1998008831A1 (fr) | 1998-03-05 |
Family
ID=16830487
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE1997/000701 WO1998008511A1 (de) | 1996-08-27 | 1997-04-07 | Verwendung von 2-phenyl-1,2-benzisoselenazol-3(2h)-one zur herstellung einer pharmazeutischen zubereitung für die behandlung der alzheimer-krankheit |
PCT/JP1997/002883 WO1998008831A1 (fr) | 1996-08-27 | 1997-08-20 | Traitement preventif ou curatif de la maladie d'alzheimer |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE1997/000701 WO1998008511A1 (de) | 1996-08-27 | 1997-04-07 | Verwendung von 2-phenyl-1,2-benzisoselenazol-3(2h)-one zur herstellung einer pharmazeutischen zubereitung für die behandlung der alzheimer-krankheit |
Country Status (29)
Country | Link |
---|---|
US (1) | US5948800A (ja) |
EP (1) | EP0826370B1 (ja) |
KR (1) | KR20000035859A (ja) |
CN (1) | CN1112922C (ja) |
AT (1) | ATE219361T1 (ja) |
AU (2) | AU3866997A (ja) |
BR (1) | BR9711259A (ja) |
CA (1) | CA2213794C (ja) |
CZ (1) | CZ295364B6 (ja) |
DE (2) | DE59707550D1 (ja) |
DK (1) | DK0826370T3 (ja) |
EE (1) | EE03953B1 (ja) |
ES (1) | ES2177849T3 (ja) |
FI (1) | FI119622B (ja) |
HK (1) | HK1020317A1 (ja) |
HU (1) | HU225264B1 (ja) |
IL (1) | IL127113A (ja) |
LT (1) | LT4602B (ja) |
LV (1) | LV12251B (ja) |
NO (1) | NO312812B1 (ja) |
NZ (1) | NZ332292A (ja) |
PL (1) | PL188481B1 (ja) |
PT (1) | PT826370E (ja) |
SI (1) | SI9720060B (ja) |
TR (1) | TR199700858A2 (ja) |
TW (1) | TW501925B (ja) |
UA (1) | UA59367C2 (ja) |
WO (2) | WO1998008511A1 (ja) |
ZA (1) | ZA977644B (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003010154A1 (en) * | 2001-07-26 | 2003-02-06 | Samsung Electronics Co. Ltd. | Seleno compounds containing nitrone moiety, their preparation and their therapeutic uses |
WO2003010153A1 (en) * | 2001-07-26 | 2003-02-06 | Samsung Electronics Co. Ltd. | N-alkyl-n-phenylhydroxylamine compounds containing metal chelating groups, their preparation and their therapeutic uses |
US7229988B2 (en) | 2001-07-26 | 2007-06-12 | Samsung Electronics Co., Ltd. | Dialkylhydroxybenzoic acid derivatives containing metal chelating groups and their therapeutic uses |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE190487T1 (de) * | 1993-10-27 | 2000-04-15 | Daiichi Seiyaku Co | Granuläre zubereitung |
JP2000016935A (ja) * | 1998-07-01 | 2000-01-18 | Dai Ichi Seiyaku Co Ltd | シクロオキシゲナーゼ阻害剤 |
EP1174423A4 (en) * | 1999-03-31 | 2008-03-19 | Arne Holmgren | SUBSTRATES FOR THIOREDOXINE REDUCTASE |
GB201102248D0 (en) | 2011-02-09 | 2011-03-23 | Isis Innovation | Treatment of bipolar disorder |
CN103965188A (zh) * | 2013-01-29 | 2014-08-06 | 中山大学 | 含硒多奈哌齐类似物 |
EP2950102A1 (en) | 2014-05-30 | 2015-12-02 | Biocross, S.L. | Method for the diagnosis of alzheimer s disease and mild cognitive impairment |
US10058542B1 (en) | 2014-09-12 | 2018-08-28 | Thioredoxin Systems Ab | Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith |
EP3067699A1 (en) | 2015-03-11 | 2016-09-14 | Neuron Bio, S.A. | Method for diagnosing alzheimer's disease |
PL237739B1 (pl) | 2018-06-06 | 2021-05-17 | Univ Gdanski | Genisteina do zastosowania do leczenia choroby Alzheimera |
CN113116888B (zh) * | 2021-04-19 | 2022-08-26 | 上海兴糖生物技术有限公司 | 依布硒啉的用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01131113A (ja) * | 1987-08-27 | 1989-05-24 | Dai Ichi Seiyaku Co Ltd | 脳障害治療剤 |
JPH04360881A (ja) * | 1990-11-23 | 1992-12-14 | Adir | 新規のベンゾセレナゾリノン化合物、これらを調製するプロセスおよびそれらを含む薬剤組成物 |
JPH07233056A (ja) * | 1993-09-03 | 1995-09-05 | Dai Ichi Seiyaku Co Ltd | リポキシゲナーゼ阻害剤 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3616923A1 (de) * | 1986-05-20 | 1987-11-26 | Nattermann A & Cie | Neue pharmazeutische verwendung von 2-phenyl-1,2-benzisoselenazol-3(2h)-on |
DE3638124C2 (de) * | 1986-11-08 | 1996-09-05 | Nattermann A & Cie | Neue pharmazeutische Verwendung von Ebselen |
JPH0238591A (ja) | 1988-07-27 | 1990-02-07 | Fujikura Ltd | 高純度銅の製造方法 |
DE4024885C2 (de) * | 1990-08-06 | 2002-07-18 | Nattermann A & Cie | Verwendung von 2-Phenyl-1,2-benzisoselenazol-3(2H)-on |
US5385726A (en) * | 1990-08-06 | 1995-01-31 | Rhone-Poulenc Rorer Gmbh | Use of 2-phenyl-1,2-benzisoselenazol-3-(2H)-one |
-
1997
- 1997-03-17 ES ES97104503T patent/ES2177849T3/es not_active Expired - Lifetime
- 1997-03-17 DE DE59707550T patent/DE59707550D1/de not_active Expired - Fee Related
- 1997-03-17 AT AT97104503T patent/ATE219361T1/de not_active IP Right Cessation
- 1997-03-17 EP EP97104503A patent/EP0826370B1/de not_active Expired - Lifetime
- 1997-03-17 PT PT97104503T patent/PT826370E/pt unknown
- 1997-03-17 DK DK97104503T patent/DK0826370T3/da active
- 1997-04-07 WO PCT/DE1997/000701 patent/WO1998008511A1/de active IP Right Grant
- 1997-04-07 SI SI9720060A patent/SI9720060B/sl not_active IP Right Cessation
- 1997-04-07 BR BR9711259A patent/BR9711259A/pt not_active Application Discontinuation
- 1997-04-07 CZ CZ1999317A patent/CZ295364B6/cs not_active IP Right Cessation
- 1997-04-07 HU HU9903213A patent/HU225264B1/hu not_active IP Right Cessation
- 1997-04-07 EE EEP199900007A patent/EE03953B1/xx not_active IP Right Cessation
- 1997-04-07 IL IL12711397A patent/IL127113A/xx not_active IP Right Cessation
- 1997-04-07 NZ NZ332292A patent/NZ332292A/en unknown
- 1997-04-07 CN CN97195890A patent/CN1112922C/zh not_active Expired - Fee Related
- 1997-07-04 UA UA99010526A patent/UA59367C2/uk unknown
- 1997-08-04 US US08/905,530 patent/US5948800A/en not_active Expired - Lifetime
- 1997-08-04 DE DE19733690A patent/DE19733690A1/de not_active Withdrawn
- 1997-08-20 WO PCT/JP1997/002883 patent/WO1998008831A1/ja not_active Application Discontinuation
- 1997-08-20 KR KR1019997001554A patent/KR20000035859A/ko not_active Application Discontinuation
- 1997-08-20 AU AU38669/97A patent/AU3866997A/en not_active Abandoned
- 1997-08-21 TW TW086112018A patent/TW501925B/zh not_active IP Right Cessation
- 1997-08-25 CA CA002213794A patent/CA2213794C/en not_active Expired - Fee Related
- 1997-08-26 PL PL97321796A patent/PL188481B1/pl not_active IP Right Cessation
- 1997-08-26 NO NO19973912A patent/NO312812B1/no not_active IP Right Cessation
- 1997-08-26 ZA ZA977644A patent/ZA977644B/xx unknown
- 1997-08-26 AU AU35298/97A patent/AU725534B2/en not_active Ceased
- 1997-08-27 TR TR97/00858A patent/TR199700858A2/xx unknown
-
1998
- 1998-10-22 LV LVP-98-231A patent/LV12251B/lv unknown
- 1998-12-11 FI FI982689A patent/FI119622B/fi not_active IP Right Cessation
-
1999
- 1999-02-23 LT LT99-016A patent/LT4602B/lt not_active IP Right Cessation
- 1999-11-29 HK HK99105534A patent/HK1020317A1/xx not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01131113A (ja) * | 1987-08-27 | 1989-05-24 | Dai Ichi Seiyaku Co Ltd | 脳障害治療剤 |
JPH04360881A (ja) * | 1990-11-23 | 1992-12-14 | Adir | 新規のベンゾセレナゾリノン化合物、これらを調製するプロセスおよびそれらを含む薬剤組成物 |
JPH07233056A (ja) * | 1993-09-03 | 1995-09-05 | Dai Ichi Seiyaku Co Ltd | リポキシゲナーゼ阻害剤 |
Non-Patent Citations (2)
Title |
---|
CELL, Vol. 77, (1994), BEHL, C., DAVIS, J.B., LESLEY, R., SCHUBERT, D., pages 817-827. * |
NEUROSCIENCE LETTERS, 185, (1995), DAWSON, D.A., MASAYASU, H. GRAHAM, D.I., MACRAE, I.M., pages 65-69. * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003010154A1 (en) * | 2001-07-26 | 2003-02-06 | Samsung Electronics Co. Ltd. | Seleno compounds containing nitrone moiety, their preparation and their therapeutic uses |
WO2003010153A1 (en) * | 2001-07-26 | 2003-02-06 | Samsung Electronics Co. Ltd. | N-alkyl-n-phenylhydroxylamine compounds containing metal chelating groups, their preparation and their therapeutic uses |
US6815459B2 (en) | 2001-07-26 | 2004-11-09 | Sam-Sung Electronics Co., Ltd. | Seleno compounds containing nitrone moiety, their preparation and their therapeutic uses |
US6949654B2 (en) | 2001-07-26 | 2005-09-27 | Sam-Sung Electronics Co., Ltd. | N-alkyl-N-phenylhydroxylamine compounds containing metal chelating groups, their preparation and their therapeutic uses |
US7229988B2 (en) | 2001-07-26 | 2007-06-12 | Samsung Electronics Co., Ltd. | Dialkylhydroxybenzoic acid derivatives containing metal chelating groups and their therapeutic uses |
US7511034B2 (en) | 2001-07-26 | 2009-03-31 | Samsung Electronics Co., Ltd. | Dialkylhydroxybenzoic acid derivatives containing metal chelating groups and their therapeutic uses |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998008831A1 (fr) | Traitement preventif ou curatif de la maladie d'alzheimer | |
CA2294247C (en) | Antioxidant enhancement of therapy for hyperproliferative conditions | |
JP2007277273A (ja) | 哺乳類細胞の増殖を治療するためのハロゲン化芳香族を含有する医薬製剤 | |
Matsuno et al. | S-Benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2, 3-dioxygenase | |
JPH05255084A (ja) | 経皮的冠動脈形成術後の再狭窄抑制剤 | |
JP2009138005A (ja) | ルテニウム(iii)錯体および複素環を含む組成物 | |
Wang et al. | Recent advances in the discovery of indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitors | |
Kotthaus et al. | New prodrugs of the antiprotozoal drug pentamidine | |
JP4841433B2 (ja) | 治療的処置 | |
EP1776103B1 (fr) | Complexes de ruthenium pour le traitement de cancers | |
JP2003201255A (ja) | アルツハイマー病予防および治療剤 | |
US20090062338A1 (en) | Nitroxides for use in treating or preventing cardiovascular disease | |
Edler et al. | Demonstration of microtubule-like structures formed with (−)-rhazinilam from purified tubulin outside of cells and a simple tubulin-based assay for evaluation of analog activity | |
Duan et al. | The advances of the structure and function of indoleamine 2, 3-dioxygenase 1 and its inhibitors | |
US6495517B2 (en) | Cyclooxygenase inhibitor | |
Oderinlo et al. | Acridone Alkaloids: In-Silico Investigation Against SARS-CoV-2 Main Protease | |
JP2002518299A (ja) | アセチルコリンレベルを増加させる方法 | |
FR2558160A1 (fr) | 3-alkoxy 2-(n-pyrrolidino)-n-pyrimidinyl ou -pyrazinyl propylamines, leur preparation et leur application en therapeutique | |
JPH02258722A (ja) | 白血球の再生を可能にする新規な医薬組成物と、医薬と、後天性免疫不全症候群の治療へのその応用 | |
EP0565658A1 (en) | Verbenone, having antielastase activity, against pulmonary emphysema | |
Samuel et al. | In-vitro Antimalarial Investigations and Molecular Docking Studies of Compounds from Trema orientalis L.(blume) Leaf Extract | |
WO1995020388A1 (fr) | Medicaments anti-vih | |
JP2010520854A (ja) | 高コレステロール血症の治療又は予防において使用するためのニトロキシド | |
JPH08310945A (ja) | 一酸化窒素合成酵素阻害剤 | |
JPH03135917A (ja) | 尿酸排泄剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) |
Free format text: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL,IS, KE, KG, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AP (GH, KE, LS, MW, SD, SZ, UG, ZW), EA, (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), EP (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OA (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD,TG) |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019997001554 Country of ref document: KR |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 1019997001554 Country of ref document: KR |
|
WWR | Wipo information: refused in national office |
Ref document number: 1019997001554 Country of ref document: KR |